Bremelanotide (PT-141) vs Melanotan II

Bremelanotide and Melanotan II are related cyclic melanocortin peptides with different clinical evidence. The approved bremelanotide acetate injection improved desire and related distress in selected premenopausal women, while small Melanotan II studies measured pigmentation and acute erections in men. No selected head-to-head trial establishes a better or safer treatment.

Research reviewed 2026-10-15. Educational information only.

Related melanocortin chemistry, different medicinal preparations

Bremelanotide, also called PT-141, and Melanotan II are synthetic cyclic peptides related to alpha-melanocyte-stimulating hormone. Their common biology involves melanocortin receptors, a family of cell-surface switches involved in pigmentation and other physiological responses. The Vyleesi label describes bremelanotide as a nonselective agonist that activates these receptors; MC1R and MC4R binding is most relevant at therapeutic exposure, while the exact mechanism of benefit in hypoactive sexual desire disorder (HSDD), meaning distressing low desire, remains unknown. Receptor activity supplies a biological connection, but does not show that the two drugs have equivalent effects.

Molecular endings also matter. The original Melanotan II pilot identifies an acetylated cyclic heptapeptide with an amide at its terminal end. The Vyleesi label identifies bremelanotide acetate with a terminal carboxyl group. The approval concerns the specified subcutaneous medicinal formulation. It cannot establish the identity, concentration or clinical performance of a vial or nasal product sold under either research name.

The main differences

Desire-related distress and penile rigidity are different outcomes

The bremelanotide phase 3 program enrolled premenopausal women with acquired, generalized hypoactive sexual desire disorder. Acquired means that low desire developed after a period without that problem; generalized means it occurs across situations or partners. The indication requires marked distress or interpersonal difficulty and excludes specified medical, psychiatric, relationship and drug-related explanations. The product is not indicated for men, postmenopausal women or general sexual-performance enhancement.

The Melanotan II experiments asked a different question. In a ten-man crossover study, men with erectile dysfunction without an identified organic cause received peptide and a preparation without peptide at separate visits. Investigators measured erection presence, duration and rigidity over six hours. An erection is a physiological response; it is not the same measurement as improved desire, relief of distress or sustained sexual satisfaction. None of these selected studies directly compared Melanotan II with bremelanotide. Wessells and colleagues (1998).

Bremelanotide improved symptom scores, with an important outcome that remained uncertain

Across two separate 24-week randomized blinded trials, 1,267 women were randomized, 1,247 entered the safety population and 1,202 entered the main efficacy analysis. Compared with placebo, the pooled increase in the desire-domain score was 0.35 points, and the reduction in the item measuring distress about low desire was 0.33 points; both comparisons had P<0.001. These differences describe improvements in reported symptoms on their respective scales. Kingsberg and colleagues (2019).

The prespecified comparison of the number of satisfying sexual events did not establish a larger increase with bremelanotide than placebo (pooled P=0.630). A later analysis of the proportion of encounters rated satisfying addresses a different question and cannot replace that event-count result. More women also stopped participating in the active groups: withdrawal for any reason was 41.9% versus 16.0% in one trial and 43.8% versus 28.4% in the other. The analysis carried the last observation forward for missing outcomes, so uneven withdrawal matters when judging the reported symptom improvements.

Melanotan II produced pigmentation and acute erections in small studies

The 1996 pilot involved three healthy men who received Melanotan II or saline in an alternating-day design. Two had increased skin pigmentation one week after exposure ended. Nausea and spontaneous erections occurred, and one participant experienced grade II sleepiness and fatigue at a higher tested exposure. A three-person study can demonstrate that a substance has effects while leaving their consistency and uncommon harms uncertain. Dorr and colleagues (1996).

In the separate ten-man erectile-dysfunction study, clinically apparent erections occurred in eight men after Melanotan II. The mean period with tip rigidity above 80% was 38.0 minutes with peptide versus 3.0 minutes with the preparation without peptide (P=0.0045). The finding supports an acute erectile response in that small selected group. It does not establish long-term satisfaction, repeated-use safety, or improvement of HSDD in women. Wessells and colleagues (1998).

A measured drug formulation has a different safety basis from unregulated products

For subcutaneous Vyleesi, the label reports a mean terminal blood elimination half-life of approximately 2.7 hours, with a 1.9–4.0 hour range. This describes the decline of measured bremelanotide during elimination; it does not define a predictable duration of sexual benefit. The selected Melanotan II efficacy studies did not supply a comparable concentration-time analysis, and six-hour erection monitoring cannot be used as a half-life.

In the bremelanotide safety population, nausea occurred in 40.0% versus 1.3% with placebo. The label also describes transient blood-pressure increases, slower heart rate and focal pigment changes, which did not resolve in every observed patient. Uncontrolled hypertension and known cardiovascular disease are contraindications. Its warnings about slower stomach emptying and reduced oral naltrexone exposure are additional consequences of the tested drug’s pharmacology. Kingsberg and colleagues (2019).

Melanotan II’s small early studies also reported nausea and other systemic effects. A poisoning report described a 39-year-old man with rapid heart rate, muscle breakdown and kidney dysfunction after internet-purchased material; creatine kinase reached 17,773 IU/L and mass spectrometry identified Melanotan II in the product. One case supplies no incidence denominator. Separately, the Australian regulator found 22–54 mg across five nasal bottles labeled 30 mg and states that no Melanotan II product is approved for supply in Australia. Product variability adds uncertainty to the molecule’s own risks. FDA also identifies immune-response and impurity concerns and cites serious Melanotan II cases. These sources do not permit a numerical safety ranking against Vyleesi. Nelson and colleagues (2012).

The clinical question determines what can be concluded

Bremelanotide has replicated controlled symptom findings for a defined HSDD population and an approved formulation, alongside frequent nausea and other restrictions. Melanotan II has small early physiological studies and a less defined clinical safety base. Shared receptor biology does not make male rigidity, female desire-related distress and skin pigmentation interchangeable outcomes. With no common patient population or direct comparison, these studies cannot establish which peptide would work better for a particular person.

Frequently asked questions

Profiles and related reading

References

1. Cosette Pharmaceuticals, Inc. VYLEESI (bremelanotide injection): Full prescribing information. DailyMed. Updated November 13, 2025; accessed October 15, 2026.

   The approved subcutaneous bremelanotide acetate formulation is indicated for acquired, generalized hypoactive sexual desire disorder: distressing low desire that developed after previously normal desire and occurs across situations in premenopausal women after specified alternative causes are excluded. The label defines cardiovascular contraindications, nausea and pigment changes.

2. Kingsberg SA, Clayton AH, Portman D, Williams LA, Krop J, Jordan R, Lucas J, Simon JA. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstetrics and gynecology. 2019;134(5):899–908. doi:10.1097/AOG.0000000000003500. PMID:31599840.

   Two separate randomized trials in premenopausal women found improved desire and related distress with injected bremelanotide versus placebo. Satisfying-event counts did not improve more than placebo; withdrawal and nausea were more frequent.

3. Dorr RT, Lines R, Levine N, Brooks C, Xiang L, Hruby VJ, Hadley ME. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life sciences. 1996;58(20):1777–1784. doi:10.1016/0024-3205(96)00160-9. PMID:8637402.

   A three-man saline-controlled pilot found increased pigmentation in two men, with nausea, fatigue and spontaneous erections. It cannot establish durable cosmetic benefit or uncommon harms.

4. Wessells H, Fuciarelli K, Hansen J, Hadley ME, Hruby VJ, Dorr R, Levine N. Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study. The Journal of urology. 1998;160(2):389–393. PMID:9679884.

   Ten men with erectile dysfunction without an identified organic cause underwent a blinded crossover study. High tip rigidity lasted 38.0 minutes with Melanotan II versus 3.0 minutes with the preparation without peptide.

5. Nelson ME, Bryant SM, Aks SE. Melanotan II injection resulting in systemic toxicity and rhabdomyolysis. Clinical toxicology (Philadelphia, Pa.). 2012;50(10):1169–1173. doi:10.3109/15563650.2012.740637. PMID:23121206.

   A man became acutely ill after internet-purchased Melanotan II, with muscle breakdown and kidney dysfunction. Analysis identified the injected material, while a single case cannot estimate risk frequency.

6. Therapeutic Goods Administration. Melanotan II tanning peptide products found to be inconsistently dosed. Safety advisory. August17,2026.

   The Australian regulator found 22–54 mg of Melanotan II across five nasal bottles labeled 30 mg and states that no Melanotan II product is approved for supply in Australia. These findings concern those sampled products.

7. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Current agency webpage accessed October15,2026.

   FDA identifies immune-response and impurity concerns for compounded Melanotan II and cites serious cases including melanoma, prolonged erection, sympathomimetic toxicity, with excessive stress-system effects such as rapid heart rate, and posterior reversible encephalopathy, a syndrome involving brain swelling and neurological symptoms. These reports do not supply a general incidence rate.